Anlotinib is a newly developed multiple receptor tyrosine kinase (RTKs) oral small molecule inhibitor, and has become a new third-line treatment option for advanced NSCLC [9, 10]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.